↓ Skip to main content

Dove Medical Press

Article Metrics

Update on the development of lurasidone as a treatment for patients with acute schizophrenia

Overview of attention for article published in Drug Design, Development and Therapy, May 2012
Altmetric Badge

Mentioned by

twitter
1 tweeter

Citations

dimensions_citation
10 Dimensions

Readers on

mendeley
77 Mendeley
Title
Update on the development of lurasidone as a treatment for patients with acute schizophrenia
Published in
Drug Design, Development and Therapy, May 2012
DOI 10.2147/dddt.s11180
Pubmed ID
Authors

Norio Yasui-Furukori

Abstract

Lurasidone is a novel benzisothiazole antipsychotic drug for the treatment of schizophrenia. Of the antipsychotic drugs, lurasidone has the highest affinity for the 5-hydroxytryptamine (5-HT)(7) receptor. Lurasidone also has high affinities for the dopamine D(2), 5HT(2A), 5-HT(1A) and α(2C) adrenergic receptors. Moreover, lurasidone has low affinities for the α(1) adrenergic, histamine H(1) and muscarinic M(1) receptors. The involvement of 5-HT(7) receptors in cognitive processes has been suggested by both pharmacological and molecular investigations. Chronic treatment with lurasidone increases neurotrophin BDNF mRNA levels in both the hippocampus (ventral and dorsal) and prefrontal cortex under basal conditions or in response to an acute swim stress. Lurasidone may potentiate N-methyl-D-aspartate receptor (NMDAR) function through antagonistic action on 5-HT(7) receptors without a direct affinity for NMDARs. These results suggest that lurasidone treatment may be a novel approach for the prevention of the development of cognitive impairment in individuals who are at risk for schizophrenia or related disorders involving cognitive impairment. In clinical trials, treatment with lurasidone was associated with significantly greater endpoint improvement versus placebo on the Positive and Negative Syndrome Scale total score after 6 weeks among subjects receiving 80 or 160 mg. The most frequent side effects of lurasidone were akathisia, nausea, parkinsonism, dizziness and somnolence. Once-daily treatment with lurasidone at 160 mg was superior to placebo based on the composite cognitive functioning measure. Lurasidone treatment produced improvements in Montgomery-Asberg Depression Rating Scale scores at 6 weeks that were significantly greater than placebo. A limitation of this review is that the majority of the data were obtained from abstracts and posters. These sources have not been subjected to the peer review processes of medical journals; thus, the results presented in these forums may require further quality review and subsequent revision prior to final publication.

Twitter Demographics

The data shown below were collected from the profile of 1 tweeter who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 77 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Poland 1 1%
Canada 1 1%
Unknown 75 97%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 11 14%
Researcher 11 14%
Other 10 13%
Student > Master 10 13%
Student > Postgraduate 8 10%
Other 17 22%
Unknown 10 13%
Readers by discipline Count As %
Medicine and Dentistry 28 36%
Psychology 12 16%
Pharmacology, Toxicology and Pharmaceutical Science 6 8%
Agricultural and Biological Sciences 4 5%
Neuroscience 3 4%
Other 11 14%
Unknown 13 17%

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 09 May 2012.
All research outputs
#10,012,005
of 12,510,237 outputs
Outputs from Drug Design, Development and Therapy
#761
of 1,315 outputs
Outputs of similar age
#84,817
of 119,508 outputs
Outputs of similar age from Drug Design, Development and Therapy
#8
of 11 outputs
Altmetric has tracked 12,510,237 research outputs across all sources so far. This one is in the 11th percentile – i.e., 11% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,315 research outputs from this source. They receive a mean Attention Score of 4.5. This one is in the 28th percentile – i.e., 28% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 119,508 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 14th percentile – i.e., 14% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 11 others from the same source and published within six weeks on either side of this one. This one is in the 18th percentile – i.e., 18% of its contemporaries scored the same or lower than it.